全文获取类型
收费全文 | 64309篇 |
免费 | 4628篇 |
国内免费 | 1045篇 |
专业分类
耳鼻咽喉 | 388篇 |
儿科学 | 1042篇 |
妇产科学 | 632篇 |
基础医学 | 2928篇 |
口腔科学 | 966篇 |
临床医学 | 8067篇 |
内科学 | 6013篇 |
皮肤病学 | 908篇 |
神经病学 | 2979篇 |
特种医学 | 1257篇 |
外国民族医学 | 9篇 |
外科学 | 4080篇 |
综合类 | 13626篇 |
一般理论 | 2篇 |
预防医学 | 6147篇 |
眼科学 | 486篇 |
药学 | 11179篇 |
229篇 | |
中国医学 | 6036篇 |
肿瘤学 | 3008篇 |
出版年
2024年 | 234篇 |
2023年 | 1141篇 |
2022年 | 2292篇 |
2021年 | 3079篇 |
2020年 | 3054篇 |
2019年 | 2457篇 |
2018年 | 2232篇 |
2017年 | 2577篇 |
2016年 | 2895篇 |
2015年 | 2733篇 |
2014年 | 7073篇 |
2013年 | 6301篇 |
2012年 | 5670篇 |
2011年 | 5310篇 |
2010年 | 4022篇 |
2009年 | 2872篇 |
2008年 | 2511篇 |
2007年 | 2330篇 |
2006年 | 1905篇 |
2005年 | 1460篇 |
2004年 | 1104篇 |
2003年 | 929篇 |
2002年 | 702篇 |
2001年 | 607篇 |
2000年 | 526篇 |
1999年 | 386篇 |
1998年 | 328篇 |
1997年 | 249篇 |
1996年 | 209篇 |
1995年 | 191篇 |
1994年 | 178篇 |
1993年 | 133篇 |
1992年 | 97篇 |
1991年 | 93篇 |
1990年 | 87篇 |
1989年 | 88篇 |
1988年 | 70篇 |
1987年 | 72篇 |
1986年 | 69篇 |
1985年 | 169篇 |
1984年 | 237篇 |
1983年 | 199篇 |
1982年 | 212篇 |
1981年 | 186篇 |
1980年 | 155篇 |
1979年 | 152篇 |
1978年 | 105篇 |
1977年 | 67篇 |
1976年 | 75篇 |
1975年 | 68篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
蒙天才 《中国继续医学教育》2020,(14):159-160
目的研究左乙拉西坦治疗小儿癫痫的疗效以及对智力的影响。方法在本院2017年4月-2019年5月收治的小儿癫痫患儿中选取74例开展研究,按照随机数表法分两组观察组和对照组,观察组37例,对照组37例,对照组采用奥卡西平进行治疗,观察组采用左乙拉西坦进行治疗,对比观察组与对照组组的治疗总有效率和智力评分变化。结果观察组与对照组比较,观察组的治疗总有效率较高,智力评分明显较高,两项对比差异有统计学意义(P <0.05)。结论左乙拉西坦治疗小儿癫痫有较好的治疗效果,治疗总有效率较高,且对患儿的智力有明显的改善作用,在实际临床小儿癫痫的治疗中具有较高的运用价值。 相似文献
2.
Four clinical trials of porcine islet transplantation have been reported, and there are verbal reports that clinical trials on much larger scales are continuing in centers in China and Russia. The four reported trials are briefly reviewed and, in the light of the present status of experimental islet xenotransplantation, consideration is given to whether such trials are currently justified. The Ethics Committee of the International Xenotransplantation Association has (1) emphasized the need for encouraging studies in non-human primates before clinical trials should be undertaken, (2) mandatory monitoring for the transfer of porcine microorganisms, and (3) careful regulation and oversight by recognized bodies. Other aspects of the topic, such as the need for informed consent, are briefly discussed. We conclude that, at the present time, more data documenting convincing efficacy, focused on clinically applicable immunosuppressive regimens, are needed to justify the initiation of closely monitored clinical trials. A clinical trial may then be justified even though the potential risk to the patients, and possibly for society, will not be zero. 相似文献
3.
4.
Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab, * etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab). 相似文献
5.
J.-P. Ortonne A. Taïeb A.D. Ormerod† D. Robertson‡ J. Foehl‡ R. Pedersen‡ C. Molta‡ B. Freundlich‡ 《The British journal of dermatology》2009,161(5):1190-1195
Background Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses.
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
6.
In this study we consider the process of the clinical encounter, and present exemplars of how assumptions of both clinicians and their patients can shift or transform in the course of a diagnostic interview. We examine the process as it is recalled, and further elaborated, in post-diagnostic interviews as part of a collaborative inquiry during reflections with clinicians and patients in the northeastern United States. Rather than treating assumptions by patients and providers as a fixed attribute of an individual, we treat them as occurring between people within a particular social context, the diagnostic interview. We explore the diagnostic interview as a landscape in which assumptions occur (and can shift), navigate the features of this landscape, and suggest that our examination can best be achieved by the systematic comparison of views of the multiple actors in an experience-near manner. We describe what might be gained by this shift in assumptions and how it can make visible what is at stake for clinician and patient in their local moral worlds—for patients, acknowledgment of social suffering, for clinicians how assumptions are a barrier to engagement with minority patients. It is crucial for clinicians to develop this capacity for reflection when navigating the interactions with patients from different cultures, to recognize and transform assumptions, to notice ‘surprises’, and to elicit what really matters to patients in their care. 相似文献
7.
目的:探讨子宫内膜萎缩疗法治疗青春期功血(DUB)的止血效果。方法:将362例平均分为观察组(采用炔诺酮、戊酸雌二醇联合疗法止血)和对照组(单用炔诺酮子宫内膜萎缩疗法止血),两组各181例,比较两组的止血效果。结果:观察组和对照组止血有效率分别为96.13%(174/181)和92.27%(167/181),两组比较差异无统计学意义(踟105);观察组和对照组控制出血时间分别为(28.69±14.87)h和(29.72±15.34)h,两组比较差异无统计学意义(踟.05)。观察组和对照组的完全止血时间分别为(32.80±19.10)h和(47.30±18.60)h,两组比较差异有统计学意义(/9〈0.05)。观察组和对照组的住院天数平均为(6.10±2.80)d和(6.9±2.60)d,观察组住院时间短于对照组(P〈0.01)。结论:炔诺酮止血疗法和炔诺酮、戊酸雌二醇联合疗法治疗青春期功血效果均较好,但炔诺酮、戊酸雌二醇联合疗法治疗效果更佳。 相似文献
8.
湿润烧伤膏治疗褥疮26例的临床体会 总被引:7,自引:0,他引:7
目的:进一步观察湿润烧伤膏对治疗褥疮的疗效,寻找最理想的治疗方法。方法:通过对26 例不同原因所致褥疮的治疗,探索湿润烧伤膏对治疗褥疮病人最合理的用药方法,创面的变化及其愈合时间。结果:25例病人创面愈合,死亡1例。结论:湿润烧伤膏治疗褥疮方法简便,实用性强,疗效显著,值得各级医院推广。 相似文献
9.
AIMS: To compare long-term (1 year) efficacy and safety of pioglitazone and gliclazide in patients with Type 2 diabetes. METHODS: This was a double-blind, multicentre, comparative, parallel group trial in 283 patients with Type 2 diabetes, who were randomized to receive 1-year treatment with pioglitazone 30-45 mg/day or gliclazide 80-320 mg/day. Drug dose was titrated on the basis of self-monitored blood glucose (SMBG) measurements and HbA1c values. The 1-year changes in HbA1c, fasting blood glucose (FBG), insulin, HOMA-S (HOmeostatic Model Assessment) and SMBG were compared. In a subgroup of patients (n = 10), systemic glucose production and utilization were determined by a combination of isotopic (deuterated glucose) and clamp techniques. RESULTS: In both groups, there were similar decreases in HbA1c (pioglitazone: -0.79%; gliclazide: -0.79%) and FBG (pioglitazone: -1.0 mmol/l; gliclazide: -0.7 mmol/l), whereas the slope of the reduction of fasting blood glucose was different between groups (P = 0.004). Insulin levels as well as insulin resistance assessed using HOMA-S decreased significantly only after pioglitazone treatment (-11.94 pmol/l and -1.03, respectively, both P = 0.002 vs. baseline). A significantly greater reduction in systemic glucose production was observed in the pioglitazone group (-2.48 micromol/kg/min, P = 0.042) than in the gliclazide group (-1.02 micromol/kg/min). A few, mild adverse events occurred in both groups. CONCLUSIONS: A comparable decrease in HbA1c and FBG was observed with pioglitazone and gliclazide. However, with pioglitazone there was a continuous decrease in FBG over 1 year, whereas gliclazide failed to maintain a similar trend. This favourable effect of pioglitazone was due to its insulin-sensitizing effect and ability to decrease systemic glucose production. 相似文献
10.
Summary UK health policy requires child and adolescent mental health service providers to demonstrate that their services are effective.
The FOCUS project has been developed to improve the availability and accessibility of research evidence and innovation, to
support purchasers in the effective commissioning of services and to help providers base service provision on evidence of
effectiveness and develop methods of evaluation. 相似文献